Patents by Inventor George H. Shimer

George H. Shimer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6505126
    Abstract: The invention provides methods for identifying nucleic acids and polypeptides derived from fungi that are useful as antifungal targets for diagnosis and/or treatment of fungal diseases. The invention also provides isolated fungal-specific nucleic acids and polypeptides comprising antifungal targets. Methods for identifying antifungal agents that interact with and/or alter the function the antifungal targets are provided.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: January 7, 2003
    Assignees: Schering-Plough Corporation, Genome Therapeutics Corporation
    Inventors: Roberta S. Hare, George H. Miller, Karen J. Shaw, George H. Shimer, Jr.
  • Publication number: 20020119573
    Abstract: The present invention provides plasmids for insertional mutagenesis in bacteria. Specifically, the invention provides plasmids comprising a transposition system including a transposon and a transposase, in which transposon insertion can be temporally regulated. The plasmids can be used to determine the relative importance of a particular gene in viability of the organism from which the gene is derived. The plasmids are particularly useful for large-scale screening of a multiplicity of genes.
    Type: Application
    Filed: February 28, 2001
    Publication date: August 29, 2002
    Inventors: Karen J. Shaw, Teresa Kenney, George H. Shimer
  • Patent number: 5516663
    Abstract: The present invention involves methods of improving the Ligase Chain Reaction (LCR.TM.) amplification schemes by modifying at least one probe end so that the probability of the probe contributing to spurious ligation and signal development is greatly reduced. Only after specific hybridization of the modified probe with true target are the modified ends "corrected" by endonuclease IV in a target dependent fashion to allow participation of the probe in the enzymatic ligation reaction. Specific modifications include 3' phosphate blocking groups and nucleic acid overhangs containing an abasic site at the point of ligation. Further embodiments include probes modified to contain ribonucleotide moieties which, after amplification, can be cleaved by RNase to destroy the amplification products and reduce the risk of contamination.
    Type: Grant
    Filed: April 19, 1993
    Date of Patent: May 14, 1996
    Assignee: Abbott Laboratories
    Inventors: Keith C. Backman, John J. Carrino, George H. Shimer, Robert R. Yocum